- Home
- HIW vs ACAD Comparison
HIW vs ACAD Comparison
Compare HIW & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIW
- ACAD
- Stock Information
- Founded
- HIW 1978
- ACAD 1993
- Country
- HIW United States
- ACAD United States
- Employees
- HIW N/A
- ACAD N/A
- Industry
- HIW Real Estate Investment Trusts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- HIW Real Estate
- ACAD Health Care
- Exchange
- HIW Nasdaq
- ACAD Nasdaq
- Market Cap
- HIW 3.1B
- ACAD 2.8B
- IPO Year
- HIW 1994
- ACAD 2004
- Fundamental
- Price
- HIW $29.65
- ACAD $16.61
- Analyst Decision
- HIW Buy
- ACAD Buy
- Analyst Count
- HIW 6
- ACAD 17
- Target Price
- HIW $32.50
- ACAD $24.00
- AVG Volume (30 Days)
- HIW 1.2M
- ACAD 1.5M
- Earning Date
- HIW 04-22-2025
- ACAD 05-07-2025
- Dividend Yield
- HIW 6.75%
- ACAD N/A
- EPS Growth
- HIW N/A
- ACAD N/A
- EPS
- HIW 0.94
- ACAD 1.36
- Revenue
- HIW $830,020,000.00
- ACAD $957,797,000.00
- Revenue This Year
- HIW $0.19
- ACAD $13.07
- Revenue Next Year
- HIW $5.20
- ACAD $9.97
- P/E Ratio
- HIW $31.55
- ACAD $12.28
- Revenue Growth
- HIW N/A
- ACAD 31.85
- 52 Week Low
- HIW $23.52
- ACAD $14.15
- 52 Week High
- HIW $36.78
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- HIW 56.87
- ACAD 36.91
- Support Level
- HIW $28.95
- ACAD $16.86
- Resistance Level
- HIW $29.74
- ACAD $17.31
- Average True Range (ATR)
- HIW 0.68
- ACAD 0.51
- MACD
- HIW 0.11
- ACAD -0.00
- Stochastic Oscillator
- HIW 88.99
- ACAD 23.24
About HIW Highwoods Properties Inc.
Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties' largest customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.